2 completed, 1 not yet recruiting. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Arrhythmia: new trials by email Literature Review of Arrhythmia trials Research Report on Arrhythmia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Relaxin Therapy for Atrial Fibrillation Relaxin, Placebo - Atrial Fibrillation (AF), Arrhythmia | Phase 1 / Phase 2 | Not yet recruiting | Deeptankar DeMazumder | 208 | 2027-01-01 | 2026-01-22 |
| Single Ascending Dose of GAP-134 as a 24-hour IV Infusion in Healthy Japanese Males GAP-134 - Arrhythmia | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 56 | 2007-10-01 | 2018-09-27 |
| Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously GAP-134 - Arrhythmia | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 72 | 2007-09-01 | 2008-03-13 |
Arrhythmias, Cardiac (3) · Atrial Fibrillation (1) · Heart Failure (1) · Stroke (1)
Cardiovascular Diseases (3) · Heart Diseases (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Brain Diseases (1) · Central Nervous System Diseases (1) · Cerebrovascular Disorders (1) · Nervous System Diseases (1) · Vascular Diseases (1)
1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid (2) · Relaxin (1)
Wyeth is now a wholly owned subsidiary of Pfizer (2) · Deeptankar DeMazumder (1)
Japan (1) · United States (1)